The genetics of antithrombin

Thrombosis Research

Volumn 169, Issue , 2018, Pages 23-29

  Corral, Javier ^a   de la Morena Barrio, María Eugenia ^a   Vicente, Vicente ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Antithrombin; Mutations; SERPINC1; Thrombosis

Indexed keywords

ALANINE; ANTITHROMBIN; ARGININE; ASPARAGINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12; CYSTEINE; DNA; GLUTAMIC ACID; GLUTAMINE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HISTIDINE; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; PHENYLALANINE; PROLINE; PROTHROMBIN; RNA; SERINE; SERINE PROTEINASE INHIBITOR; THREONINE; THROMBIN; TRANSFERRIN; TRYPSIN INHIBITOR; UNINDEXED DRUG; VALINE; ANTITHROMBIN III; SERPINC1 PROTEIN, HUMAN;

ALG 12 GENE; ALGORITHM; ALLELE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; ANTITHROMBIN DEFICIENCY TYPE I; ANTITHROMBIN DEFICIENCY TYPE II; ANTITHROMBIN DEFICIENCY TYPE IIB; ARTERY THROMBOSIS; BINDING SITE; CLINICAL EXAMINATION; CONGENITAL ANTITHROMBIN DEFICIENCY; CONGENITAL DISORDER; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 1; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DNA FLANKING REGION; ENZYME INHIBITION; EXON; FAMILIAL DISEASE; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE INSERTION; GENE LOCATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GLYCOSYLATION; HEREDITY; HUMAN; MISSENSE MUTATION; MOLECULAR GENETICS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PMM2 GENE; POINT MUTATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; RISK REDUCTION; RNA SPLICING; RNA STABILITY; SANGER SEQUENCING; SERPINC1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; STRUCTURE ANALYSIS; THROMBOPHILIA; THROMBOSIS PREVENTION; TYPE IIA REACTIVE SITE DEFICIENCY; TYPE IIB HEPARIN BINDING SITE DEFICIENCY; VEIN THROMBOSIS; ANIMAL; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; MOLECULAR MODEL; MUTATION;

ANIMALS; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION;

EID: 85049560014     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2018.07.008     Document Type: Review

References (47)

1. Toulon, P., Jacquot, C., Capron, L., Frydman, M.O., Vignon, D., Aiach, M., Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb. Haemost. 57 (1987), 263–268.
2. Bjork, I., Olson, S.T., Antithrombin. A bloody important serpin. Adv. Exp. Med. Biol. 425 (1997), 17–33.
3. Corral, J., Vicente, V., Carrell, R.W., Thrombosis as a conformational disease. Haematologica 90 (2005), 238–246.
4. Olson, S.T., Bjork, I., Sheffer, R., Craig, P.A., Shore, J.D., Choay, J., Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 267 (1992), 12528–12538.
5. Lane, D.A., Caso, R., Antithrombin: structure, genomic organization, function and inherited deficiency. Baillieres Clin. Haematol. 2 (1989), 961–998.
6. Levy, J.H., Sniecinski, R.M., Welsby, I.J., Levi, M., Antithrombin: anti-inflammatory properties and clinical applications. Thromb. Haemost. 115 (2016), 712–728.
7. O'Reilly, M.S., Pirie-Shepherd, S., Lane, W.S., Folkman, J., Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285 (1999), 1926–1928.
8. Guerrero, J.A., Teruel, R., Martinez, C., Arcas, I., Martinez-Martinez, I., de la Morena-Barrio, M.E. et al., Protective role of antithrombin in mouse models of liver injury. J. Hepatol. 57 (2012), 980–986.
9. Luengo-Gil, G., Calvo, M.I., Martín-Villar, E., Aguila, S., Bohdan, N., Antón, A.I. et al., Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase. Sci. Rep., 8, 2016, 27544.
10. Bucciarelli, P., Passamonti, S.M., Biguzzi, E., Gianniello, F., Franchi, F., Mannucci, P.M. et al., Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J. Thromb. Haemost. 10 (2012), 1783–1791.
11. Egeberg, O., Inherited antithrombin deficiency causing thrombophilia. Thromb. Diath. Haemorrh. 13 (1965), 516–530.
12. Ishiguro, K., Kojima, T., Kadomatsu, K., Nakayama, Y., Takagi, A., Suzuki, M. et al., Complete antithrombin deficiency in mice results in embryonic lethality. J. Clin. Invest. 106 (2000), 873–878.
13. Tait, R.C., Walker, I.D., Davidson, J.F., Islam, S.I., Mitchell, R., Antithrombin III activity in healthy blood donors: age and sex related changes and prevalence of asymptomatic deficiency. Br. J. Haematol. 75 (1990), 141–142.
14. Martinelli, I., De S, V., Mannucci, P.M., Inherited risk factors for venous thromboembolism. Nat. Rev. Cardiol. 11 (2014), 140–156.
15. Stevens, S.M., Woller, S.C., Bauer, K.A., Kasthuri, R., Cushman, M., Streiff, M. et al., Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J. Thromb. Thrombolysis 41 (2016), 154–164.
16. Lijfering, W.M., Brouwer, J.L., Veeger, N.J., Bank I, Coppens, M., Middeldorp, S. et al., Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 113 (2009), 5314–5322.
17. Bauer, K.A., Nguyen-Cao, T.M., Spears, J.B., Issues in the diagnosis and management of hereditary antithrombin deficiency. Ann. Pharmacother. 50 (2016), 758–767.
18. Mahmoodi, B.K., Brouwer, J.L., Ten Kate, M.K., Lijfering, W.M., Veeger, N.J., Mulder, A.B. et al., A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J. Thromb. Haemost. 8 (2010), 1193–1200.
19. Corral, J., Vicente, V., Puzzling questions on antithrombin: diagnostic limitations and real incidence in venous and arterial thrombosis. Thromb. Res. 135 (2015), 1047–1048.
20. Caspers, M., Pavlova, A., Driesen, J., Harbrecht, U., Klamroth, R., Kadar, J. et al., Deficiencies of antithrombin, protein C and protein S - practical experience in genetic analysis of a large patient cohort. Thromb. Haemost. 108 (2012), 247–257.
21. Luxembourg, B., Delev, D., Geisen, C., Spannagl, M., Krause, M., Miesbach, W. et al., Molecular basis of antithrombin deficiency. Thromb. Haemost. 105 (2011), 635–646.
22. Toderici, M., de la Morena-Barrio, M.E., Padilla, J., Miñano, A., Anton, A.I., Iniesta, J.A. et al., Identification of regulatory mutations in SERPINC1 affecting vitamin D response elements associated with antithrombin deficiency. PLoS One, 11, 2016, e0159987.
23. de la Morena-Barrio, M.E., Anton, A.I., Martinez-Martinez, I., Padilla, J., Minano, A., Navarro-Fernandez, J. et al., Regulatory regions of SERPINC1 gene: identification of the first mutation associated with antithrombin deficiency. Thromb. Haemost. 107 (2012), 430–437.
24. Martinez-Martinez, I., Johnson, D.J., Yamasaki, M., Navarro-Fernandez, J., Ordonez, A., Vicente, V. et al., Type II antithrombin deficiency caused by a large in-frame insertion. Structural, functional and pathological relevance. J. Thromb. Haemost. 10 (2012), 1859–1866.
25. Aguila, S., Izaguirre, G., Martínez-Martínez, I., Vicente, V., Olson, S.T., Corral, J., Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities. J. Biol. Chem. 292 (2017), 16513–16520.
26. de la Morena-Barrio, M.E., Sandoval, E., Llamas, P., Wypasek, E., Toderici, M., Navarro-Fernandez, J. et al., High levels of latent antithrombin in plasma from patients with antithrombin deficiency. Thromb. Haemost. 117 (2017), 880–888.
27. Gettins, P.G., Olson, S.T., Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance. Biochem. J. 473 (2016), 2273–2293.
28. Cooper, P.C., Coath, F., Daly, M.E., Makris, M., The phenotypic and genetic assessment of antithrombin deficiency. Int. J. Lab. Hematol. 33 (2011), 227–237.
29. Javela, K., Engelbarth, S., Hiltunen, L., Mustonen, O., Puurunen, M., Great discrepancy in antithrombin activity measured using five commercially available functional assays. Thromb. Res. 132 (2013), 132–137.
30. Jennings, I., Kitchen, S., Woods, T.A., Preston, F.E., Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin. Thromb. Hemost. 31 (2005), 66–72.
31. Kristensen, S.R., Rasmussen, B., Pedersen, S., Bathum, L., Detecting antithrombin deficiency may be a difficult task—more than one test is necessary. J. Thromb. Haemost. 5 (2007), 617–618.
32. Moore, G.W., de Jager, N., Cutler, J.A., Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio. Thromb. Res. 135 (2015), 161–166.
33. Orlando, C., Heylen, O., Lissens, W., Jochmans, K., Antithrombin heparin binding site deficiency: a challenging diagnosis of a not so benign thrombophilia. Thromb. Res. 135 (2015), 1179–1185.
34. Ungerstedt, J.S., Shulman, S., Egberg, N., Antovic, J., Blombäck, N., Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?. Blood 99 (2002), 2271–2272.
35. Perry, D.J., Daly, M., Tait, R.C., Walker, I.D., Brown, K., Beauchamp, N.J. et al., Antithrombin Cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. Thromb. Haemost. 79 (1998), 249–253.
36. Corral, J., Hernandez-Espinosa, D., Soria, J.M., Gonzalez-Conejero, R., Ordonez, A., Gonzalez-Porras, J.R. et al., Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 109 (2007), 4258–4263.
37. Mushunje, A., Zhou, A., Carrell, R.W., Huntington, J.A., Heparin-induced substrate behavior of antithrombin Cambridge II. Blood 102 (2003), 4028–4034.
38. Friedberg, E.C., Hot news: temperature-sensitive humans explain hereditary disease. BioEssays 23 (2001), 671–673.
39. Beauchamp, N.J., Pike, R.N., Daly, M., Butler, L., Makris, M., Dafforn, T.R. et al., Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 92 (1998), 2696–2706.
40. Bruce, D., Perry, D.J., Borg, J.Y., Carrell, R.W., Wardell, M.R., Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn→Asp). J. Clin. Invest. 94 (1994), 2265–2274.
41. Navarro-Fernandez, J., de la Morena-Barrio, M.E., Padilla, J., Miñano, A., Bohdan, N., Aguila, S. et al., Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate risk of thrombosis that causes a transient antithrombin deficiency. Thromb. Haemost. 116 (2016), 146–154.
42. Martinez-Martinez, I., Navarro-Fernandez, J., Ostergaard, A., Gutierrez-Gallego, R., Padilla, J., Bohdan, N. et al., Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood 120 (2012), 900–904.
43. Raja, S.M., Chhablani, N., Swanson, R., Thompson, E., Laffan, M., Lane, D.A. et al., Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. J. Biol. Chem. 278 (2003), 13688–13695.
44. Martinez-Martinez, I., Navarro-Fernandez, J., Aguila, S., Minano, A., Bohdan, N., de la Morena-Barrio, M.E. et al., The infective polymerization of conformationally unstable antithrombin mutants may play a role in the clinical severity of antithrombin deficiency. Mol. Med. 18 (2012), 762–770.
45. Zhou, A., Huntington, J.A., Carrell, R.W., Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 94 (1999), 3388–3396.
46. de la Morena-Barrio, M.E., Martinez-Martinez, I., de Cos, C., Wypasek, E., Roldan, V., Undas, A. et al., Hypoglycosylation is a common finding in antithrombin deficiency in the absenceof a SERPINC1 gene defect. J. Thromb. Haemost., 2016, 1549–1560.
47. Jaeken, J., Congenital disorders of glycosylation. Ann. N. Y. Acad. Sci. 1214 (2010), 190–198.